Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IV Carbamazepine as Replacement for Oral Carbamazepine in Epilepsy
NCT01128959Phase 3
Key facts
- Status
- Completed
- Start
- Jun 2010
- Primary completion
- Jan 2013
- Countries
- 1
- Sponsor
- Lundbeck
- Modality
- Small Molecules
- Drugs
- carbamazepine
- Conditions
- epilepsy
01
Overview
Phase 3, open-label, single-arm trial of carbamazepine in epilepsy, sponsored by Lundbeck. Primary endpoint: Adverse Events. Started Jun 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Intravenous Carbamazepine (IV CBZ)
Patients receive IV Carbamazepine as a replacement for oral Carbamazepine.
03
Who it enrols
Adult patients with epilepsy on stable higher doses of oral carbamazepine (1200-2000 mg/day).
04
Endpoints
Primary
Adverse Events
Secondary
Seizure Frequency
Beyond the preview
Go deeper on NCT01128959.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128959.